Chemotherapy for Metastatic Gastric Cancer: Does Age Matter? A Single-Center, Retrospective, Real-World Study

Liao, Po-Wei; Cheng, Shao-Bin; Chou, Chia-Lin; Lin, Hsin-Chen; Lin, Cheng‐Hsien; Chen, Tsung-Chih; Hsu, Chiann‐Yi; Teng, Chieh‐Lin Jerry; Shih, Yu-Hsuan

doi:10.1177/11795549221123617

Cited by 3 publications

(2 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…divided 306 patients receiving palliative chemotherapy into two groups at the age of 70 years and compared the clinical demographics, prognosis and hematological toxicity of chemotherapy between the two groups. It was found that the progression-free survival and overall survival were the same and the incidence of hematological toxicity was similar ( 91 ), which suggests that age is not a limiting condition for palliative chemotherapy in elderly patients with metastatic gastric carcinomas.…”

Section: Palliative Chemotherapymentioning

confidence: 99%

Application and progress of palliative therapy in advanced gastric carcinomas

Luo

Luo²,

Zhao³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Gastric carcinomas have high morbidity and mortality. It produces no noticeable symptoms in the early stage while causing complex complications in its advanced stage, making treatment difficult. Palliative therapy aims to relieve the symptoms of cancer patients and focuses on improving their quality of life. At present, five palliative therapies for advanced gastric carcinomas are offered: resection, gastrojejunostomy, stenting, chemotherapy, and radiotherapy. In recent years, palliative therapy has been used in the clinical treatment of advanced gastric carcinomas and related complications because of its efficacy in gastric outlet obstruction and gastric bleeding. In the future, multimodal and interdisciplinary palliative therapies can be applied to control general symptoms to improve patients’ condition, prolong their lifespan and improve their quality of life.

show abstract

Section: Palliative Chemotherapymentioning

confidence: 99%

Application and progress of palliative therapy in advanced gastric carcinomas

Luo

Luo²,

Zhao³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…8 In another retrospective study, 306 patients receiving chemotherapy treatment were divided into two categories under and over 70 years of age and no statistically significant difference was found in progression-free survival (PFS) and OS between the two groups. 9 The aim of our study was to compare the efficacy and side effects of single-agent and double-agent chemotherapy regimens in the first-line treatment of patients with HER-2 negative metastatic GC aged 80 years and older, which is part of our routine practice.…”

Section: Introductionmentioning

confidence: 99%

Comparison of efficacy and tolerability of single agent and double agent chemotherapy regimens in first-line treatment of elderly patients with her-2 negative metastatic gastric cancer

Güner,

Ürün

2024

JCHOR

View full text Add to dashboard Cite

Aims: Chemotherapy remains a cornerstone in treating metastatic gastric cancer (GC), yet the management of elderly patients, who often face distinct challenges, lacks comprehensive guidelines. The aim of this study was to compare the efficacy and side effects of single-agent and double-agent chemotherapy regimens in first-line treatment of elderly patients with HER-2 negative metastatic GC. Methods: We retrospectively evaluated HER-2 negative metastatic GC patients aged 80 years and older who were treated at Van Yüzüncü Yıl University Medical Faculty Dursun Odabaşı Medical Center Oncology Clinic between 2010 and 2023. Demographic characteristics, treatment regimens and responses, prognostic factors, grade 3-4 toxicity, progression-free survival (PFS), and overall survival (OS) were analyzed. Results: The mean age of 56 patients was 82.6 ± 2.3 years and 24 (42.9%) of them were women. Single-agent chemotherapy was administered to 33 (58.9%) patients, while 23 (41.1%) received double-agent chemotherapy. The median OS was 5 months (95% CI, 2.9 to 7.1) in the single-agent group and 10 months (95% CI, 4.2 to 15.8) in the double-agent group (p = 0.237), although there was a numerical difference, it was not statistically significant. Median PFS was longer with double-agent chemotherapy, but not statistically significant (6 months vs. 4 months, p = 0.668). No statistically significant difference was found in the side effect rates of patients receiving single and double-agent chemotherapy. Conclusion: In our study, despite the absence of statistical significance in the survival rates among patients receiving double chemotherapeutic agents, their survival was twice as long as that of individuals receiving a single agent. Furthermore, no significant differences in terms of side effects were observed. These findings suggest that, even in individuals aged 80 years and older, a preference for double-agent chemotherapy should be considered when feasible.

show abstract

The efficacy of adjuvant chemotherapy for older adults with stage II/III gastric cancer: a retrospective cohort study

Shih,

Lin,

Liao

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

Background Adjuvant chemotherapy is recommended as the standard treatment for patients with stage II/III resected gastric cancer. However, it is unclear whether older patients also benefit from an adjuvant chemotherapy strategy. This study aimed to investigate the clinical impact of adjuvant chemotherapy in older patients with stage II/III gastric cancer. Methods This retrospective, real-world study analyzed 404 patients with stage II/III gastric cancer visited at our institute between January 2009 and December 2019. The clinical characteristics and outcomes of patients aged 70 years or older who received adjuvant chemotherapy were compared with those who did not receive this type of treatment. Propensity score analysis was performed to mitigate selection bias. Results Of the 404 patients analyzed, 179 were aged 70 years or older. Fewer older patients received adjuvant chemotherapy than did younger patients (60.9% vs. 94.7%, respectively; P < 0.001). Among patients aged 70 years or older, those who received adjuvant chemotherapy had improved disease-free survival (DFS) (5-year DFS rate, 53.1% vs. 30.4%; P < 0.001) and overall survival (OS) (5-year OS rate, 68.7% vs. 52.1%; P = 0.002) compared to those who did not receive adjuvant chemotherapy. A similar survival benefit was observed in the propensity-matched cohort. Multivariate analysis showed that more advanced stage was associated with poorer OS. Receipt of adjuvant chemotherapy was independently associated with a decreased hazard of death (hazard ratio (HR), 0.37; 95% confidence intervals (CI), 0.20–0.68; P = 0.002). Conclusions Adjuvant chemotherapy may benefit older stage II/III gastric cancer patients aged ≥ 70 years. Further prospective studies are needed to confirm these findings.

show abstract

Chemotherapy for Metastatic Gastric Cancer: Does Age Matter? A Single-Center, Retrospective, Real-World Study

Cited by 3 publications

References 86 publications

Application and progress of palliative therapy in advanced gastric carcinomas

Application and progress of palliative therapy in advanced gastric carcinomas

Comparison of efficacy and tolerability of single agent and double agent chemotherapy regimens in first-line treatment of elderly patients with her-2 negative metastatic gastric cancer

The efficacy of adjuvant chemotherapy for older adults with stage II/III gastric cancer: a retrospective cohort study

Contact Info

Product

Resources

About